Advertisement

Topics

PharmaCyte Biotech Successfully Completes Multiple Course Ifosfamide Study

09:00 EDT 17 Apr 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Bo...

Other Sources for this Article

Investor Relations:
PharmaCyte Biotech, Inc.
Dr. Gerald W. Crabtree, 917.595.2856
Investor Relations Department
Info@PharmaCyte.com

NEXT ARTICLE

More From BioPortfolio on "PharmaCyte Biotech Successfully Completes Multiple Course Ifosfamide Study"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...